Supply of Children's Tylenol suspension will be normalized

Cancellation of permission for the first half of the year by suspending operation of Hyangnam plant

Registration of Ultracet ER for Handok Technology Transfer

The product license was withdrawn due to the suspension of the operation of the Jansen Hyangnam plant in Korea, but the new product re-licensed due to technology transfer will be listed as starting in August.

 

This includes child Tylenol suspension, and attention is being paid to whether supply and demand will be normalized with new benefits, given that the product has recently been struggling to supply.

 

According to the industry, Ultracet ER, Ultracet Semi, Ultracet Semi ER, and Children's Tylenol suspension will be newly reimbursed as of August 1.

 

The upper limit is the same as before.

 

Following the withdrawal of the Hyangnam plant, the permission for these products was withdrawn in the first half of last year, and the salary was scheduled to be deleted.

 

In response, Janssen was re-approved as a new product by transferring technology to Handok in the case of three types, including Ultracet ER.

 

Children's Tylenol suspension was also newly licensed as an imported item.

 

Three types, including Ultracet ER, were scheduled to be removed in November and Children's Tylenol suspension in September.

 

However, as new products are listed, prescription gaps are not expected to occur at all.

 

Ultracet ER is a product developed directly by Janssen Korea in 2010, not by global Janssen.

 

Since there were no imported items, Janssen Korea decided to transfer its technology to Handok, and has been taking steps.

 

In March, a new product produced by Handok was approved, and this time, it was even paid.

 

Children's Tylenol suspension was approved in early February as an imported item manufactured in Indonesia.

 

However, due to difficulties in supply, products distributed in Australia were urgently introduced in May during the COVID-19 epidemic.

 

Johnson & Johnson Korea, which distributes and sells Children's Tylenol suspension, announced that supply will be normalized in August.

 

Attention is focusing on whether the supply will begin in earnest with this new product.